Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction

NCT02245477 | Unknown DMC

• 1 other identifier: Beni-Suef 5
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

In this study we explore To explore the role of maternal serum vascular endothelial growth factor (VEGF) in pregnancies complicated by foetal growth restriction.

Conditions

Foetal Growth Restriction

Keywords

Serum VEGF, FGR

Outcome Measures

Primary Outcomes (1)

• Obstetric ultrasound

  Patients with gestational age 28-36 weeks were included in our study. Patients with SGA were defined by obstetric ultrasound as estimated fetal weight was below the10thcentile. Twice weekly CTGs and Umbilical artery (UA) Doppler were done. Women with abnormal CTGs or UA Doppler were excluded from the study. A follow up scan was done 2 weeks later and FGR will be diagnosed if fetal weight had altered.

  from 28 weeks gestation to 36 weeks gestation

Secondary Outcomes (1)

• Serum Vascular Endothelial growth factor

  3 months until delivery

Study Arms (2)

Obstetric Ultrasoud

Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.

Device: obstetric Ultrasound

Serum Vascular Endothelial Growth Factor

Serum VEGF concentration will be determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat. No. DVEOO) manufactured by R \& D Systems, Inc , (Minneapolis, MN, USA).

Other: serum Vascular Endothelial Growth Factor

Interventions

obstetric Ultrasound DEVICE

Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.

Obstetric Ultrasoud

serum Vascular Endothelial Growth Factor OTHER

Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees

Serum Vascular Endothelial Growth Factor

Eligibility Criteria

• Age: 20 Years - 40 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients with gestational age 28-36 weeks were included in our study. Patients with SGA were defined by obstetric ultrasound as estimated fetal weight was below the10thcentile.Twice weekly CTGs and Umbilical artery (UA) Doppler were done. Women with abnormal CTGs or UA Doppler were excluded from the study. A follow up scan was done 2 weeks later and FGR will be diagnosed if fetal weight had faltered.

You may qualify if:

• Age 20-40 years
• Gestational age 28-36 weeks
• Fetal growth restriction
• Patient consents to the procedure.
• BMI 20-30

You may not qualify if:

• Preeclampsia
• Diabetes Mellitus
• Fetal congenital anomalies

Sponsors & Collaborators

• Beni-Suef University: lead

Study Sites (1)

Nesreen Abdel Fattah Abdullah Shehata

Cairo, Egypt

RECRUITING

MeSH Terms

Conditions

Fetal Growth Retardation

Condition Hierarchy (Ancestors)

Fetal Diseases; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Growth Disorders; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Nesreen A Shehata, MD

CONTACT

00201227866337; nesoomar@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Obstetrics and Gynecology

Study Record Dates

• First Submitted: September 17, 2014
• First Posted: September 19, 2014
• Study Start: September 1, 2014
• Primary Completion: June 1, 2021
• Study Completion: June 1, 2021
• Last Updated: February 2, 2021

Record last verified: 2021-01

Locations

EG (1)